Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

ConclusionFor up to 3  years of continuous treatment, upadacitinib was well tolerated in Japanese patients, with a similar safety profile to that of short-term studies and durable long-term response rates for skin clearance and itch improvement.Trial RegistrationClinicalTrials.gov identifier, NCT03661138.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research